Hosted on MSN22d
Thinking of Colored Contacts for Halloween? Here’s Why You Should Be Cautious
To safely wear colored contact lenses, consult an eye care professional, follow proper hygiene practices, and only purchase ...
Yahoo29d
What Happens if You Accidentally Fall Asleep With Contacts In? MD’s Tips
While sleeping with your lenses should be avoided, the FDA has approved various types of contact lenses for extended wear. That includes lenses you can wear anywhere from overnight to up to 30 days.
FierceBiotech1d
Caris scores FDA approval for multi-cancer companion diagnostic test
Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a ...
FDA approves Emrosi for rosacea in adults
The U.S. Food and Drug Administration has approved Journey Medical's Emrosi (minocycline hydrochloride) for the treatment of ...
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Reuters1d
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
PTC Therapeutics' gene therapy is already approved in the European Union, Great Britain, and Israel. The drugmaker will also ...
Medscape6d
FDA Approved Obe-cel, a Novel CD19 CAR T Product for ALL
Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.
The Telegraph22d
FDA offers Halloween safety tips
Whether your Halloween plans are for adults or kids, there’s plenty to consider before choosing a costume, putting on makeup and eating a bag full of treats. To help you and your loved ones enjoy a ...
FDA grants Sonoma 510(k) approval for Microdacyn Hydrogel
The FDA posted online 510(k) approval for Sonoma Pharmaceuticals (SNOA)’ Microdacyn Hydrogel, which is intended for use of acute and ...
The American Journal of Managed Care7d
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate ...